Enbrel® (etanercept) is a prescription medicine used to treat five chronic diseases, including moderate to severe rheumatoid arthritis. These highlights do not include all the information needed to use Enbrel safely and effectively. See full prescribing information for Enbrel. Enbrel® (etanercept). What is Enbrel (etanercept) and what is it used for? of Product Characteristics ( SPC) for Enbrel these can be found at the electronic Medicines Compendium.
|Published (Last):||13 June 2011|
|PDF File Size:||5.36 Mb|
|ePub File Size:||16.85 Mb|
|Price:||Free* [*Free Regsitration Required]|
Long-term experience with Enbrel was generally comparable to the original week study and did not reveal any new safety findings. Posology Rheumatoid arthritis 25 mg Enbrel administered twice weekly is the recommended dose. Some parts of the site may not work properly if you choose not to accept cookies. Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept to patients and volunteers, increased etanercept concentrations were not observed in patients with acute renal failure.
Join Subscribe or Register Existing user? Plain language summary Why was the study conducted? Latest Celebrating a year of career highlights 12 DEC Percent of Patients Achieving Endpoints.
Both TNFRs exist naturally in membrane-bound and soluble forms. Paediatric Plaque Psoriasis Outcomes at 12 Weeks.
Offer subject to change or discontinuation without notice. With continued therapy, responses were maintained up to 48 weeks.
J Manag Care Pharm. Patients can enroll by visiting EnbrelSupport. The long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs DMARD has not been established.
In a pooled data set of clinical trials, the overall incidence of opportunistic infections was 0. If any serious allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and appropriate therapy initiated. For the full list of excipients, see section 6.
Enbrel 25 mg powder and solvent for solution for injection
Continue typing to refine. We aimed to generate a comprehensive analytical data package from stability testing of key quality attributes, consistent with regulatory enbtel, to determine whether the product profile of etanercept is maintained at ambient temperature. At week 12, more patients randomised to Enbrel had positive efficacy responses e. This alternative storage condition represents further innovation in the etanercept product lifecycle, providing greater flexibility and enhanced overall convenience for patients.
In part 1, all patients received 0. Use of biologic agents such as etanercept in the treatment of rheumatic diseases has brought considerable benefits in terms of symptom control as well as in other patient-relevant outcomes.
Treatment of polyarthritis rheumatoid factor positive or negative and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. Of patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the patients remaining on Enbrel continued to improve from month 3 through month 7, while those who received placebo did not improve.
Powder and solvent for solution for injection powder for injection. Patients with complete ankylosis of the spine were not included in the study. This article has been cited by other articles in PMC. Marketed by Amgen Inc. Author information Copyright and License information Disclaimer.
Enbrel is reconstituted with 1 ml water for injections before use, and administered by subcutaneous injection. No dose-limiting toxicities observed in trials. Both assays were run on the same batches in an analytical method crossover exercise at the and month timepoints.
Re-introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same magnitudes of responses as patients who received Enbrel without interruption of therapy based on results of open-label studies. Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae.
Enbrel treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque psoriasis. Serious infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia, cholecystitis, osteomyelitis, gastritis, appendicitis, Streptococcal fasciitis, myositis, septic shock, diverticulitis and abscess.
Allergic reactions associated with Enbrel administration have been reported commonly. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.
The half-life is long, approximately 70 hours. The powder is white. The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. There is no income requirement to participate in this program. A total of patients were enrolled, from which were treated with Enbrel. Alcoholic hepatitis In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in patients treated with Enbrel was significantly higher after 6 months.
Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if necessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Enbrel is not recommended during pregnancy. Early and aggressive treatment, including the use of novel biologic agents, has been shown to lead to favorable patient outcomes in reducing synovial inflammation, delaying joint damage, and maintaining functional status.
Find a Medicine Results
However, due to their complexity, these drugs are normally stored under refrigerated conditions to maintain stability. For patients who received 25 mg twice weekly throughout the study, the PASI 75 response continued to improve between weeks 12 and With twice-weekly doses, it is anticipated that steady-state concentrations are approximately twice as high as those observed after single doses.
You will be re-directed back to this page where you will have the ability to comment. Study 3 evaluated patients and had the same inclusion criteria as study 2.
You can find information about moderate to severe rheumatoid arthritis RAmoderate to severe plaque psoriasis, psoriatic arthritis, moderate to severe polyarticular juvenile idiopathic arthritis JIAand ankylosing spondylitis AS.